Commentary

Podcast

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

Author(s):

Fact checked by:

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Julia Rotow, MD, about data shared at the 2024 ASCO Annual Meeting that demonstrated the central nervous system (CNS) activity of datopotamab deruxtecan (Dato-DXd) and osimertinib (Tagrisso) in patients with non–small cell lung cancer (NSCLC). Dr Rotow is the clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts.

In our exclusive interview, Dr Rotow discussed insights on the phase 3 LAURA trial (NCT03521154), including how osimertinib decreased the risk of CNS relapse in patients with unresectable, stage III, EGFR-mutant NSCLC. She also highlighted findings from the analysis of the intracranial activity of Dato-DXd in patients with advanced or metastatic NSCLC in the phase 2 TROPION-Lung05 trial (NCT04484142).

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Marc Machaalani, MD
Kimmie Ng, MD, MPH
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Kimmie Ng, MD, MPH
Ann H. Partridge, MD, MPH
Alicia Morgans, MD, MPH
Paolo Tarantino, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School